87721-62-8 Usage
Description
Flestolol is a nonselective, competitive, ultra-short-acting beta-adrenergic antagonist that is metabolized by plasma esterases with an elimination half-life of approximately 6.5 minutes.
Uses
Used in Pharmaceutical Industry:
Flestolol is used as a beta-blocker for the treatment of various cardiovascular conditions, such as hypertension, angina, and arrhythmias. Its ultra-short-acting nature allows for rapid onset and offset of action, making it suitable for use in situations where rapid control of heart rate and blood pressure is required.
Used in Anesthesia:
Flestolol is used as an adjunct to anesthesia for the management of tachycardia and hypertension during surgical procedures. Its rapid onset and short duration of action enable precise control of heart rate and blood pressure, ensuring patient safety and comfort during surgery.
Used in Emergency Medicine:
Flestolol is used as an emergency treatment for hypertensive crisis, where rapid reduction of blood pressure is necessary to prevent complications such as stroke, heart attack, or organ damage. Its ultra-short-acting profile allows for quick intervention and effective management of blood pressure spikes.
Used in Research:
Flestolol is used as a research tool in the study of beta-adrenergic receptors and their role in various physiological processes. Its nonselective and competitive nature allows for the investigation of the effects of beta-blockade on different receptor subtypes and their associated signaling pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 87721-62-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,7,2 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 87721-62:
(7*8)+(6*7)+(5*7)+(4*2)+(3*1)+(2*6)+(1*2)=158
158 % 10 = 8
So 87721-62-8 is a valid CAS Registry Number.
InChI:InChI=1/C15H22FN3O4/c1-15(2,9-18-14(17)22)19-7-10(20)8-23-13(21)11-5-3-4-6-12(11)16/h3-6,10,19-20H,7-9H2,1-2H3,(H3,17,18,22)
87721-62-8Relevant articles and documents
2-hydroxypropylamine heteroaryl ester derivatives
-
, (2008/06/13)
The present invention relates to compounds of the general formula STR1 wherein Ar represents a substituted or unsubstituted heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR2 COR1, --NR2 CONR1 R3, --NR2 SO2 R1, NR2 SO2 NR1 R3, or --NR2 COOR1, wherein R1, R2 and R3 may be alike or different and may be hydrogen, alkyl, alkoxyalkyl cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R1 is not hydrogen when B is --NR2 SO2 R1 or --NR2 COOR1, or R1 and R3 may together with N form a 5 to 7 membered heterocyclic group and the pharmaceutically acceptable salts thereof. The compounds exhibit beta-adrenergic blocking activity and are also useful in the treatment of glaucoma.
propanolamines. 1. Novel β-Blockers with Ultrashort Duration of Action
Kam, Sheung-Tsam,Matier, William L.,Mai, Khuong X.,Barcelon-Yang, Cynthia,Borgman, Robert J.,et al.
, p. 1007 - 1016 (2007/10/02)
Novel propanolamines were synthesized and investigated as potential ultrashort-acting β-adrenergic receptor blockers.Many of these analogues exhibited good potency and short duration.The N-ureidoalkyl analogue 85 (ACC-9089) has a potency equal to propranolol and a duration of action of about 21 min in the dog.It has been selected as a candidate for further clinical study.Structure-activity relationships and structure-duration relationships for these new β-blockers are also discussed.